文献速递瓣膜外科

免缝合主动脉生物瓣Perceval美国前瞻性IDE试验一年结果

Prospective US investigational device exemption trial of a sutureless aortic bioprosthesis: One-year outcomes.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-10-23

这项美国多中心单臂IDE试验纳入300例主动脉瓣病患者,评估免缝合牛心包瓣Perceval的安全性与有效性。器械植入成功率96.3%,院内死亡率1.3%,一年全因死亡率5.2%,卒中1%,新永久起搏器10.7%。一年时98%患者心功能NYHA I/II级,左室质量指数下降且生活质量改善。

要点

  • Perceval免缝合瓣植入成功率96.3%,院内死亡率1.3%,低于风险模型预测。
  • 一年全因死亡率5.2%,卒中1%,瓣膜相关再手术2.1%。
  • 新永久起搏器发生率10.7%,其中2.5%为三度房室传导阻滞。

核心结论

  • Perceval免缝合主动脉瓣在低中危患者中安全有效,死亡率低于预测模型。
  • 一年血流动力学获益持续且生活质量改善。

研究设计与样本

  • 前瞻性单臂FDA IDE试验,2013年6月至2015年1月在美国18个中心纳入300例患者。
  • 平均年龄76.7±7.7岁,男性54.3%,STS预测死亡风险中位数2.8%。
  • 6.7%为二叶式主动脉瓣,1.7%有既往主动脉瓣置换史。
  • 26.7%采用微创入路,37.8%合并其他手术。

主要发现

  • 院内(≤30天)死亡1.3%(n=4),观察/预期比0.40。
  • 一年全因死亡5.2%(n=15),卒中1%(n=3),心内膜炎1.7%(n=5)。
  • 新永久起搏器10.7%(n=30/281),其中三度房室传导阻滞2.5%(n=7/281)。
  • 一年瓣膜相关再手术2.1%(n=6),98%患者NYHA I/II级。

临床怎么用

  • 对于适合生物瓣的主动脉瓣病患者,可考虑免缝合瓣以简化植入并缩短手术时间。
  • 需关注术后新永久起搏器风险,尤其房室传导阻滞高危患者。
  • 一年随访显示血流动力学与生活质量改善,支持该器械用于主动脉瓣病管理。

局限性

  • 单臂设计,无随机对照,结论需谨慎解读。
  • 随访仅一年,长期耐久性未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We performed a prospective, single-arm clinical trial approved under a Food and Drug Administration Investigational Device Exemption to assess safety and efficacy of Perceval, a sutureless bovine pericardial aortic valve representing the initial US experience. METHODS: From June 2013 to January 2015, 300 patients (mean age 76.7 ± 7.7 years, 54.3% men, 37.3% ≥80 years, median Society of Thoracic Surgeons Predicted Risk of Mortality 2.8%), underwent Perceval valve implantation at 18 centers across the United States. Twenty patients (6.7%) had a bicuspid aortic valve and 5 (1.7%) patients had previous aortic valve replacement. A minimally invasive approach was used in 80 (26.7%) and concomitant procedures were performed in 113 (37.8%) patients. RESULTS: Two hundred eighty-nine patients (96.3%) were successfully implanted. Operative mortality (≤30 days) was 1.3% (n = 4) (observed to expected ratio of 0.40). One-year results included all-cause mortality in 5.2% (n = 15), stroke in 1% (n = 3), and endocarditis in 1.7% (n = 5). New permanent periprocedural pacemaker rate was 10.7% (n = 30/281); 2.5% (n = 7/281) resulted from third-degree atrioventricular block. One-year valve-related reoperation was 2.1% (n = 6). At 1-year follow-up, 98% of patients were in New York Heart Association class I/II, left ventricular mass index decreased from 103.5 ± 30.1 g/m2 at discharge to 95.8 ± 27.1 g/m2 (P = .001), and 3 (1.3%) moderate paravalvular leaks were identified. Health-related quality of life score increased from 62.7 ± 21.8 before surgery to 85.5 ± 17.8 at 1 year (P < .001). CONCLUSIONS: These results confirm the safety and effectiveness of the Perceval sutureless aortic valve replacement in study patients with lower mortality than expected from a risk prediction model. Persistent hemodynamic benefit and improvement in quality of life at 1 year support the importance of this device in the management of aortic valve disease.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Suri RM, Javadikasgari H, Heimansohn DA, et al. Prospective US investigational device exemption trial of a sutureless aortic bioprosthesis: One-year outcomes. J Thorac Cardiovasc Surg. 2018. PMID: 30553598. doi:10.1016/j.jtcvs.2018.08.121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。